Table 1.
Clozapine license and monitoring and risk management requirements.
| Status | Current UK guidelines |
Current US guidelines |
||
|---|---|---|---|---|
| General population | Benign ethnic neutropenia (BEN) criteria | General population | BEN criteria | |
| Green * | ||||
| White cell count (WCC) (× 109/l) | >3.5 | >3.0 | Not required | Not required |
| Absolute neutrophil count (ANC) (× 109/l) | >2.0 | >1.5 | >2.0 | >2.0 |
| Amber # | ||||
| WCC (× 109/l) | 3.0–3.5 | 2.5–3.0 | Not required | Not required |
| ANC (× 109/l) | 1.5–2.0 | 1.0–1.5 | 1.0–1.5 | 0.5–1.0 |
| Red ^ | ||||
| WCC (× 109/l) | <3.0 | <2.5 | Not required | Not required |
| ANC (× 109/l) | <1.5 | <1.0 | <1.0 | <0.5 |
*
Continue treatment.
#
Increase monitoring frequency.
^
Discontinue treatment.
ANC, absolute neutrophil count; BEN criteria, benign ethnic neutropenia criteria; WCC, white cell count.